凯莱英(002821) - 2024 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2024 was RMB 1.40 billion, a decrease of 37.76% compared to RMB 2.25 billion in the same period last year[6] - Net profit attributable to shareholders was RMB 281.97 million, down 55.27% from RMB 630.35 million year-on-year[6] - Basic and diluted earnings per share were both RMB 0.76, a decrease of 55.81% compared to RMB 1.72 in the previous year[6] - In Q1 2024, the company's net profit was approximately ¥279.53 million, a decrease of 55.5% compared to ¥627.89 million in the same period last year[24] - Operating profit for Q1 2024 was approximately ¥294.69 million, compared to ¥709.95 million in Q1 2023, reflecting a decline of 58.5%[24] - The company reported a total comprehensive income of approximately ¥279.82 million in Q1 2024, compared to ¥622.76 million in Q1 2023[24] Revenue Breakdown - Revenue from small molecule business reached RMB 1.22 billion, with a year-on-year growth of 26.58% after excluding the impact of large orders from the previous year[8] - Revenue from emerging businesses was RMB 176 million, a decline of 29.30% year-on-year due to the ongoing impact of the domestic investment and financing environment[8] - Total operating revenue for the first quarter was CNY 1,399,808,311.93, a decrease of 37.8% compared to CNY 2,249,034,497.62 in the previous period[23] Cash Flow and Liquidity - Cash flow from operating activities was RMB 490.67 million, down 62.36% from RMB 1.30 billion in the same period last year[6] - Total cash and cash equivalents at the end of Q1 2024 were approximately ¥4.77 billion, down from ¥5.38 billion at the end of Q1 2023[26] - The company received cash from operating activities totaling approximately ¥1.87 billion in Q1 2024, down from ¥2.86 billion in the previous year[25] - Cash flow from investing activities in Q1 2024 was negative at approximately -¥284.60 million, compared to -¥327.22 million in Q1 2023[26] Assets and Liabilities - The total assets at the end of the reporting period were RMB 19.84 billion, a slight increase of 0.38% from RMB 19.77 billion at the end of the previous year[6] - Total liabilities decreased to CNY 2,234,464,626.88 from CNY 2,257,179,887.55, indicating a reduction in financial obligations[22] - The company’s equity attributable to shareholders rose to CNY 17,578,908,929.36 from CNY 17,479,716,341.34, reflecting growth in shareholder value[22] Shareholder Information - The top 10 shareholders hold significant stakes, with ASYMCHEM LABORATORIES owning 31.16% and HKSCC NOMINEES LIMITED holding 7.46% of the shares[15] - The company reported a total of 115,133,168 shares held by ASYMCHEM LABORATORIES, representing the largest single shareholder[15] - The company has a total of 6,555,504 shares held by Tianjin Guorong Business Consulting Co., Ltd., which is involved in margin trading[16] - The company has established a stock repurchase plan approved in the recent shareholder meetings, indicating a commitment to enhancing shareholder value[18] Strategic Initiatives - The company is accelerating its overseas capacity layout and enhancing operational management systems to improve overall profitability[7] - The report indicates that the company is actively engaging in market expansion and strategic initiatives, including potential mergers and acquisitions[18] - The company plans to repurchase A-shares with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a repurchase price capped at RMB 157 per share[18] - The company plans to expand its market presence and invest in new product development to drive future growth[21] Research and Development - The report highlights the company's ongoing research and development efforts in new products and technologies, although specific details were not disclosed[18] - Research and development expenses were CNY 169,442,435.66, slightly up from CNY 162,096,744.48, indicating continued investment in innovation[23]